Metopot 25 Tablet ER contains Metoprolol Succinate 23.75 mg, a selective beta-1 adrenergic receptor blocker used primarily in the management of cardiovascular conditions. This extended-release formulation allows for once-daily dosing, providing sustained beta-blockade throughout the day. Metoprolol Succinate exerts its therapeutic effect by reducing heart rate, myocardial contractility, and cardiac output, thereby decreasing oxygen demand and improving cardiac efficiency. It is commonly prescribed for hypertension, angina pectoris, and heart failure, as well as for the prevention of myocardial infarction and management of arrhythmias. The extended-release nature of Metopot 25 ensures stable plasma concentrations, minimizing fluctuations and enhancing patient compliance. It is contraindicated in patients with severe bradycardia, cardiogenic shock, or overt heart failure requiring intravenous inotropic support. Caution is advised in individuals with asthma, diabetes mellitus, or peripheral vascular disease. Common adverse effects may include fatigue, dizziness, and gastrointestinal disturbances. Dose adjustments are necessary in hepatic impairment. Metopot 25 should be administered under medical supervision, with gradual dose titration to achieve optimal therapeutic outcomes while monitoring for adverse reactions and contraindications. This medication should not be abruptly discontinued to avoid exacerbation of angina or precipitating myocardial infarction.